Prima BioMed (NASDAQ:IMMP) Shares Pass Below Fifty Day Moving Average – Here’s Why

Prima BioMed Ltd (NASDAQ:IMMP)’s stock price passed below its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $0.58 and traded as low as $0.4573. Prima BioMed shares last traded at $0.4681, with a volume of 854,377 shares traded.

Prima BioMed News Summary

Here are the key news stories impacting Prima BioMed this week:

• Negative Sentiment: Multiple law firms, including Rosen, Bronstein, Gewirtz & Grossman, Pomerantz, Bernstein Liebhard, and Faruqi & Faruqi, announced or promoted a class action lawsuit against Immutep, signaling increased legal and reputational risk. Article Title
• Negative Sentiment: The lawsuits allege harm to investors and securities-fraud violations, with one report specifically noting senior executives named as defendants, which may raise uncertainty around management and future disclosures. Article Title
• Neutral Sentiment: Several notices are simply deadline reminders for investors to contact counsel or seek lead-plaintiff status, which adds to the news flow but does not introduce new operational developments for the company. Article Title

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on IMMP shares. Citizens Jmp lowered shares of Prima BioMed from an “outperform” rating to a “market perform” rating in a research report on Friday, March 13th. Maxim Group lowered shares of Prima BioMed from a “buy” rating to a “hold” rating in a research report on Friday, March 13th. Robert W. Baird lowered shares of Prima BioMed from an “outperform” rating to a “neutral” rating and decreased their target price for the stock from $7.00 to $1.00 in a research report on Friday, March 13th. Finally, Wall Street Zen upgraded shares of Prima BioMed to a “hold” rating in a research report on Saturday, April 18th. Three research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Reduce” and a consensus target price of $5.50.

Prima BioMed Trading Up 1.2%

The company’s 50-day moving average is $0.49 and its 200-day moving average is $1.83.

Prima BioMed (NASDAQ:IMMP) last posted its quarterly earnings results on Friday, January 30th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter. The company had revenue of $1.37 million for the quarter.

Institutional Trading of Prima BioMed

An institutional investor recently raised its position in Prima BioMed stock. Jane Street Group LLC boosted its stake in Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 51,574 shares of the biotechnology company’s stock after purchasing an additional 6,617 shares during the period. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 2.32% of the company’s stock.

About Prima BioMed

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.